JP2010530356A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530356A5
JP2010530356A5 JP2010500974A JP2010500974A JP2010530356A5 JP 2010530356 A5 JP2010530356 A5 JP 2010530356A5 JP 2010500974 A JP2010500974 A JP 2010500974A JP 2010500974 A JP2010500974 A JP 2010500974A JP 2010530356 A5 JP2010530356 A5 JP 2010530356A5
Authority
JP
Japan
Prior art keywords
composition
env
sequence signature
hiv
infectious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010500974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530356A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/003965 external-priority patent/WO2008118470A2/en
Publication of JP2010530356A publication Critical patent/JP2010530356A/ja
Publication of JP2010530356A5 publication Critical patent/JP2010530356A5/ja
Pending legal-status Critical Current

Links

JP2010500974A 2007-03-27 2008-03-27 急性伝染ｈｉｖエンベロープ・サイン Pending JP2010530356A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90725907P 2007-03-27 2007-03-27
PCT/US2008/003965 WO2008118470A2 (en) 2007-03-27 2008-03-27 Acute transmitted hiv envelope signatures

Publications (2)

Publication Number Publication Date
JP2010530356A JP2010530356A (ja) 2010-09-09
JP2010530356A5 true JP2010530356A5 (enExample) 2011-05-12

Family

ID=39789201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500974A Pending JP2010530356A (ja) 2007-03-27 2008-03-27 急性伝染ｈｉｖエンベロープ・サイン

Country Status (7)

Country Link
US (1) US20100104596A1 (enExample)
EP (1) EP2129395A4 (enExample)
JP (1) JP2010530356A (enExample)
CN (1) CN101969997A (enExample)
AU (1) AU2008231306A1 (enExample)
CA (1) CA2682206A1 (enExample)
WO (1) WO2008118470A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181776T1 (hr) 2008-11-18 2019-02-08 Beth Israel Deaconess Medical Center, Inc. Antivirusna cjepiva sa poboljšanom staničnom imunogenosti
WO2011109104A2 (en) * 2010-03-03 2011-09-09 The Uab Research Foundation Molecular clone of hiv-1
WO2011126576A2 (en) * 2010-04-09 2011-10-13 Duke University Genetic signatures in the envelope glycoprotein of hiv-1
EP3526236B1 (en) 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585979B1 (en) * 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
US20030215793A1 (en) * 2002-01-17 2003-11-20 Hahn Beatrice H. Complete genome sequence of a simian immunodeficiency virus from a wild chimpanzee
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
CN1852734B (zh) * 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
DE10343901A1 (de) * 2003-09-19 2005-04-14 Basf Ag Amidgruppenhaltige Ethylenterpolymere und ihre Verwendung
WO2005035555A1 (en) * 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies

Similar Documents

Publication Publication Date Title
Plotkin Complex correlates of protection after vaccination
Zhang et al. Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection
Laguette et al. Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins
Ferrantelli et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
Shum et al. Aptamer-based therapeutics: new approaches to combat human viral diseases
US12440550B2 (en) Immunogenic compositions and uses thereof
Jary et al. Kaposi’s sarcoma-associated herpesvirus, the etiological agent of all epidemiological forms of Kaposi’s sarcoma
JP2010530356A5 (enExample)
EP2359851A3 (en) MVA expressing modified hiv envelope, gag, and pol genes
De Goede et al. Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection
SG178909A1 (en) Generation of a broad t-cell response in humans against hiv
JP2015500854A5 (enExample)
Xie et al. Intranasal immunization with recombinant vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice
HRP20171697T1 (hr) Varijanta hiv gp-120
WO2008091398A3 (en) Jc virus vaccine
EP2567967A3 (en) Method of using adenoviral vectors to induce an immune response
RU2012130551A (ru) Штамм вируса гриппа а/17/виктория/2011/89 (h3n2) для производства живой гриппозной интраназальной вакцины для взрослых и для детей
JP2008500963A5 (enExample)
JP2007515386A5 (enExample)
Dunham et al. FIV as a model for AIDS vaccine studies
Dutry et al. Antibody-Dependent Enhancement (ADE) of influenza infection and its possible role in the pathogenesis of influenza
Manafi et al. Understanding the performance of HIV-1 viral vector vaccines: adenovirus and poxvirus case studies
Kanizsai et al. Antiretroviral effect of 4-thio-uridylate against human immunodeficiency virus type 1
YAMANOUCHI Exploring virus world
Popov et al. The molecular evolution of the most dangerous emerging virus infections